SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MRK: Merck & Co., Inc.
MRK 85.98-0.3%Oct 31 9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: brian h1/3/2005 1:25:34 PM
  Read Replies (1) of 22
 
It explains why MRK drops in price today.

Scientist Ups Estimate Of Ill-Effects From Vioxx - Paper

NEW YORK (Dow Jones)--The scientist at the center of a dispute over the safety of the anti-inflammatory Vioxx has vowed to publish research that suggests up to 139,000 Americans have died or have been seriously injured as a result of taking the drug, The Financial Times reported on its Web Site Monday.

The likely appearance in the Lancet of a revised version of a paper by Dr. David Graham, an employee of the Food and Drug Administration, will fuel debate over the effectiveness of the US drug regulatory system and may spur additional litigation against Merck (MRK), the manufacturer of Vioxx, the paper reported.

Graham originally estimated in August that 28,000 Americans had died or suffered debilitating heart attacks as a result of taking Vioxx since it was first approved in 1999, the paper added.

In an interview with the Financial Times, Graham said he was determined to go ahead with publication of his updated analysis, even though he had been threatened with dismissal by the FDA if he wrote and published the paper.

"The FDA has suppressed the paper and maligned me in the media but never responded. The proper place for scientific information is in a peer-reviewed scientific journal," he said.

The FDA only allowed him to present the data in his personal capacity and banned him from publishing it in the Lancet. A few weeks later, Merck withdrew Vioxx, claiming it had done so voluntarily and identified health risks in its own study, the Times reported.

Re-analyzing the data, including recent information from Merck's study, Dr Graham said that between 89,000 and 139,000 people had been seriously affected by the drug. He originally provided those estimates to a congressional hearing in November, the Financial Times reported.

Dow Jones Newswires
01-03-050655ET
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext